Watch CSBR. Know when insiders buy.
One email the day a filing lands. Free.
CSBR
CHAMPIONS ONCOLOGY, INC.
4.72
−0.04 −0.84%
USD · close Oct 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $65.6MP/E —DIV YIELD —FCF YIELD -7.68%REV TTM $59.4M +4.4%NET INCOME −$1.1M −123.7%NET CASH —52W 4.69 – 7.80SEC XBRL · TTM TO Invalid Date
How CSBR rewrote its risk factors
Text kept
90%
of sentences unchanged
Added
10
new sentences
Dropped
10
sentences removed
Length
+0
words, now 5,587
New in FY2026
- For the fiscal year ended April 30, 2026, the Company had a net loss of approximately $1.2 million, an accumulated deficit of approximately $81.1 million, and a cash balance of $4.9 million.
- The Company used cash in operations of approximately $4.5 million for the twelve months ending April 30, 2026.
- We believe that our cash on hand, together with expected cash flows from operations, are adequate to fund our operations through at least August 2027.
- If the future growth and operating results of our business are not as strong as anticipated and/or our market capitalization declines, this could result in an impairment of our goodwill.
- As of July 23, 2026, we had 14,013,902 shares of common stock issued and 13,893,569 outstanding.
- Collectively, our officers, our directors and four significant stockholders own or exercise voting and investment control of approximately 71% of our outstanding common stock as of July 23, 2026.
- Our Chairman of the Board of Directors resides in Israel and we have several customers with their operations located in Israel, and, therefore, our leadership continuity and results may be adversely affected by political, economic, and military instability in Israel.
- While we do not have a physical facility located in Israel, our Chairman of the Board of Directors resides there and we have several customers whose operations are based there.
- It is currently not possible to predict the duration or severity of the ongoing wars with Iran and its proxies, or its effects on our business, operations, and financial conditions.
- The ongoing wars could disrupt our customers' business and operations.
Gone since FY2025
- For the fiscal year ended April 30, 2025, the Company had net income of approximately $4.7 million, an accumulated deficit of approximately $79.9 million, and a cash balance of $9.8 million.
- The Company also had cash provided by operations of approximately $7.4 million for the twelve months ending April 30, 2025.
- We believe that our cash on hand, together with expected cash flows from operations, are adequate to fund our operations through at least August 2026.
- If the future growth and operating results of our business are not as strong as anticipated and/or our market capitalization declines, this could impact the assumptions used in calculating the fair value of goodwill.
- As of July 21, 2025, we had 13,897,505 shares of common stock issued and 13,777,170 outstanding.
- Collectively, our officers, our directors and three significant stockholders own or exercise voting and investment control of approximately 72% of our outstanding common stock as of July 21, 2025.
- Our Chief Executive Officer resides in Israel and we have several customers with their operations located in Israel, and, therefore, our leadership continuity and results may be adversely affected by political, economic, and military instability in Israel.
- While we do not have a physical facility located in Israel, our Chief Executive Officer resides there and we have several customers whose operations are based there.
- It is currently not possible to predict the duration or severity of the ongoing war or its effects on our business, operations, and financial conditions.
- The ongoing war is rapidly evolving and developing, and could disrupt our customers' business and operations.
Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2025 ↗, FY2026 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.